Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118135 | 0.92 | NAMPT (0.42) | NAMPTALDH1A1EPHX2 | |
| SCHEMBL4131436 | 0.91 | NAMPT (0.38) | NAMPTPOLBALDH1A1EPHX2TBXAS1 | |
| SCHEMBL4131207 | 0.91 | THRB (0.40) | NAMPTTHRBALDH1A1ATM | |
| SCHEMBL4125917 | 0.91 | HTR2A (0.36) | ALDH1A1EPHX2 | |
| SCHEMBL4125960 | 0.87 | NAMPT (0.38) | NAMPT | |
| SCHEMBL4125815 | 0.87 | ATM (0.36) | NAMPTTHRBPOLBALDH1A1EPHX2 | |
| SCHEMBL4131003 | 0.87 | NAMPT (0.37) | NAMPTTHRBALDH1A1ATM | |
| SCHEMBL4126106 | 0.86 | NAMPT (0.40) | NAMPTPOLBALDH1A1TBXAS1 | |
| SCHEMBL4135433 | 0.86 | NAMPT (0.37) | NAMPTTHRBPOLBALDH1A1ATM | |
| SCHEMBL4125768 | 0.85 | ATM (0.35) | NAMPTEPHX2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NAMPT 2129/4885THRB 3537/4885POLB 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.